Tuesday, March 28, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Medical Countermeasures

Emerging H7N9 Influenza Demonstrates Antiviral Drug Resistance

by Global Biodefense Staff
May 29, 2013

Emergence of Avian Influenza A(H7N9)Drug resistance to the primary influenza treatment Tamiflu appears to develop easily with the new H7N9 avian flu, according to a new study recently published in The Lancet.

H7N9 has already demonstrated resistance to the only other class of flu treatments available, known as adamantane drugs, leaving few tools to fight the infections should the virus become more easily transmissible among people.

The study authors found that in 14 H7N9 patient specimens in China, two developed resistance to Tamiflu. Doctors in Taiwan treating a patient that had recently traveled to China identified a third such resistant mutation.

“The apparent ease with which antiviral resistance emerges in (H7N9) viruses is concerning,” said the study authors. “It needs to be closely monitored and considered in future pandemic response plans.”

The study demonstrated treatment with Tamiflu, even administered 48 hours or more after disease onset, reduced the viral load in the majority of patients and is still a recommended treatment course for H7N9 cases.

Read the study at The Lancet: Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance (.pdf)

Tags: AntiviralsAvian InfluenzaEmerging ThreatsH7N9InfluenzaPandemic

Related Posts

DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
NISTCHO: New Living Reference Material for Producing Monoclonal Antibodies
Medical Countermeasures

NISTCHO: New Living Reference Material for Producing Monoclonal Antibodies

January 12, 2023
Load More

Latest News

Biodefense Headlines – 26 March 2023

March 26, 2023
Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC